Skip to main content
TipRanks
Go Ultimate75% OFF

Cell Impact AB (CI) AI Stock Analysis

2 Followers
SE:CI

Cell Impact AB

(Nasdaq OMX AB:CI)

Select Model
Rating:40.9Neutral
Price Target:SEK 0.02â–²(6.25% Upside)
Action:upgraded
Date:11/18/26

The overall score is extremely low, reflecting a company in severe financial distress. The most significant factor is the fundamentally unprofitable business model, evidenced by negative gross margins and massive cash burn that is rapidly consuming the company's remaining equity. This is compounded by a persistently bearish technical trend, with the stock price deeply below all key moving averages. The negative P/E ratio confirms the lack of earnings power. The only mitigating factor is a clean balance sheet with minimal debt, but this cushion is shrinking quickly.

Positive Factors
Low leverageThe low debt burden gives Cell Impact some financial flexibility relative to a highly leveraged industrial company. This can reduce refinancing pressure and leave greater capacity to support operations or invest in production capabilities while the business works toward profitability.
Negative Factors
Severe unprofitabilityThe company has not yet demonstrated an economically sustainable operating model: its very small revenue base is outweighed by substantial losses and negative gross profit. This indicates that scale, pricing, or cost structure must improve materially before growth can translate into durable earnings.

Cell Impact AB (CI) vs. iShares MSCI Sweden ETF (EWD)

-100%-75%-50%-25%0%25%SE:CI-94.74%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 5.28M
Dividend Yield
―
Average Volume (3M)
12.34M
Price to Earnings (P/E)
-0.1
Beta (1Y)
0.72
Revenue Growth
-15.92%
EPS Growth
62.91%
Country
Sweden
Employees
26
Sector
Industrials
Sector Strength
63
Industry
Manufacturing - Metal Fabrication

Cell Impact AB Business Overview & Revenue Model

Company Description

Cell Impact AB (publ) is a Swedish firm that specializes in the global production and distribution of bipolar flow plates, which are crucial components for hydrogen fuel cells. The company's products include plates designed with meticulously precise...

Cell Impact AB Financial Statement Overview

Summary

Financial performance is critically weak. The income statement shows a revenue collapse and deeply negative gross margins, leading to massive net losses. The cash flow statement confirms an unsustainable cash burn rate that threatens the company's viability. The balance sheet is the only relative bright spot, with very low debt, but equity is being rapidly eroded. Overall, the core business is fundamentally unprofitable and faces existential risk.

Income Statement

8Very Negative

Balance Sheet

55Neutral

Cash Flow

5Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.63M5.57M37.33M47.26M76.81M71.35M
Gross Profit-148.82M-121.42M5.42M25.45M36.94M34.88M
EBITDA-43.91M-55.03M-71.45M-97.72M-86.22M-67.85M
Net Income-113.19M-131.98M-100.43M-121.40M-104.22M-79.85M
Balance Sheet
Total Assets141.13M163.37M261.25M381.93M401.51M238.72M
Cash, Cash Equivalents and Short-Term Investments11.23M10.86M20.39M99.89M164.67M28.56M
Total Debt8.48M32.54M30.92M42.75M44.70M19.51M
Total Liabilities19.51M42.34M42.16M78.56M77.17M96.10M
Stockholders Equity121.63M121.03M219.08M303.37M324.35M142.63M
Cash Flow
Free Cash Flow-31.74M-47.29M-76.66M-152.75M-174.32M-140.39M
Operating Cash Flow-31.02M-45.36M-62.23M-100.97M-105.93M-86.08M
Investing Cash Flow-712.00K2.30M-14.43M-51.78M-68.40M-54.32M
Financing Cash Flow36.31M33.68M-2.84M88.09M310.47M17.01M

Cell Impact AB Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.02

Price Trends

50DMA0.02Negative
100DMA0.04Negative
200DMA0.08Negative

Market Momentum

MACD-0.00Negative
RSI50.73Neutral
STOCH90.91Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CI, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 50.73 is Neutral, neither overbought nor oversold. The STOCH value of 90.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CI.

Cell Impact AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

SE:CI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
SE:OSSDSE:OSSD45NeutralSEK 352.90M-6.59――-11.89%-11.85%
SE:ANNXSE:ANNX44NeutralSEK 75.67M-2.02―――7.33%
SE:CLBIOSE:CLBIO42NeutralSEK 375.01M-26.29――77.77%47.65%
SE:CISE:CI41NeutralSEK 23.89M-0.06――-15.92%62.91%
SE:FLUOSE:FLUO40UnderperformSEK 482.30M-6.55―――-23.57%
SE:SCIBSE:SCIB40UnderperformSEK 129.62M-0.68-415.20%―54.94%47.64%

* Industrials Sector Average

Performance Comparison

-50%0%50%SE:CISE:SCIBSE:ANNXSE:OSSDSE:CLBIOSE:FLUODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:CI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:CICell Impact AB0.02-0.29-94.82%
SE:SCIBSciBase Holding AB9.10-17.05-65.20%
SE:ANNXAnnexin Pharmaceuticals AB8.90-13.95-61.06%
SE:OSSDOssDsign AB2.98-7.42-71.35%
SE:CLBIOCorline Biomedical AB14.00-5.05-26.51%
SE:FLUOFluoGuide A/S29.50-8.50-22.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026